Brief: BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
20/10/2025 13:18
Oct 20 (Reuters) - Bioatla Inc BCAB.O: BIOATLA PRESENTS PROMISING INTERIM DATA FROM ITS PHASE 1 TRIAL WITH BA3182 IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT ESMO 2025 Source text: ID:nGNX2rjvTq Further company coverage: BCAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bioatla
See all newsBrief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM